News
MORF
28.07
+0.32%
0.09
Morphic Holding Launches New Stock Offering, Ends Previous Deal
TipRanks · 2h ago
MORPHIC HOLDING INC - ENTERED INTO A SALES AGREEMENT WITH TD SECURITIES (USA) LLC
Reuters · 2h ago
MORPHIC - MAY OFFER AND SELL, FROM TIME TO TIME AT ITS SOLE DISCRETION, SHARES OF ITS COMMON STOCK, HAVING PRICE OF UP TO $350 MLN
Reuters · 2h ago
Morphic Holding files automatic mixed shelf
Seeking Alpha · 3h ago
MORPHIC HOLDING FILES FOR MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING
Reuters · 3h ago
Morphic Holding’s Financial Strength and Promising MORF-057 Clinical Trials Spur Buy Rating
TipRanks · 12h ago
Stifel Nicolaus Remains a Hold on Morphic Holding (MORF)
TipRanks · 12h ago
Morphic Holding (MORF) Gets a Buy from RBC Capital
TipRanks · 13h ago
Morphic Holding’s Buy Rating Affirmed: Promising Trials and Strong Financial Outlook
TipRanks · 15h ago
MORF Stock Earnings: Morphic Holding Beats EPS for Q1 2024
Morphic Holding reported earnings per share of -91 cents for the first quarter of 2024. The company did not report any revenue for the quarter. Morphic Holding's earnings were above the analyst estimate for EPS of -93 cents. The stock is down 1.7% today.
Investorplace · 1d ago
Morphic Holding Inc reports results for the quarter ended in March - Earnings Summary
Morphic Holding Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 91 cents per share. The mean expectation of ten analysts was for a loss of 93 cents. Reported revenue was zero; analysts expected zero. Shares had fallen by 21.3% this quarter and lost 4.1% this year.
Reuters · 1d ago
Morphic Holding, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 1d ago
Morphic GAAP EPS of -$0.91
Seeking Alpha · 1d ago
Morphic Holding Q1 2024 GAAP EPS $(0.91) Beats $(0.94) Estimate
Benzinga · 1d ago
*Morphic Holding 1Q Total Operating Expenses $53.6M>MORF
Dow Jones · 1d ago
*Morphic Holding 1Q Research, Development Expenses $42.4M >MORF
Dow Jones · 1d ago
Press Release: Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
Morphic Therapeutic reports corporate highlights and financial results for the first quarter 2024. Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis. Appointed Dr. Simon Cooper as Chief Medical Officer. First patient to be dosed in GARNET Phase 2 study of MORf-057 for Crohn's disease in second quarter. Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities.
Dow Jones · 1d ago
*Morphic Holding 1Q Loss/Shr 91c >MORF
Dow Jones · 1d ago
Press Release: Morphic Announces Corporate -2-
These forward-looking statements speak only as of the date hereof. Morphic Holding, Inc. Disclaims any obligation to update these statements. The company's financial results for the three months ended March 31, 2018 are reported on a diluted basis. The company has released financial tables to follow.
Dow Jones · 1d ago
BRIEF-Morphic Q1 Basic EPS USD -0.91
Reuters · 1d ago
More
Webull provides a variety of real-time MORF stock news. You can receive the latest news about Morphic Holding through multiple platforms. This information may help you make smarter investment decisions.
About MORF
Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.